Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.
Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg PG, Davidson JA, Nicolau JC, Corbalan R, Hirshberg B, Frederich R, Im K, Umez-Eronini AA, He P, McGuire DK, Leiter LA, Raz I, Scirica BM; SAVOR-TIMI 53 Steering Committee and Investigators. Udell JA, et al. Among authors: steg pg. Diabetes Care. 2015 Apr;38(4):696-705. doi: 10.2337/dc14-1850. Epub 2014 Dec 31. Diabetes Care. 2015. PMID: 25552421 Clinical Trial.
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Booth J, Topol EJ; CHARISMA Investigators. Bhatt DL, et al. Among authors: steg pg. Am Heart J. 2005 Sep;150(3):401. doi: 10.1016/j.ahj.2005.03.017. Am Heart J. 2005. PMID: 16169314 Clinical Trial.
Impact of carotid endarterectomy on medical secondary prevention after a stroke or a transient ischemic attack: results from the Reduction of Atherothrombosis for Continued Health (REACH) registry.
Touzé E, Mas JL, Röther J, Goto S, Hirsch AT, Ikeda Y, Liau CS, Ohman EM, Richard AJ, Wilson PW, Steg PG, Bhatt DL; REACH Registry Investigators. Touzé E, et al. Among authors: steg pg. Stroke. 2006 Dec;37(12):2880-5. doi: 10.1161/01.STR.0000249411.44097.5b. Epub 2006 Oct 26. Stroke. 2006. PMID: 17068303
Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry).
Steinberg BA, Steg PG, Bhatt DL, Fonarow GC, Zeymer U, Cannon CP; REACH Registry Investigators. Steinberg BA, et al. Among authors: steg pg. Am J Cardiol. 2007 May 1;99(9):1212-5. doi: 10.1016/j.amjcard.2006.12.039. Epub 2007 Mar 16. Am J Cardiol. 2007. PMID: 17478144
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ, Fox KA; CHARISMA Investigators. Bhatt DL, et al. Among authors: steg pg. J Am Coll Cardiol. 2007 May 15;49(19):1982-8. doi: 10.1016/j.jacc.2007.03.025. Epub 2007 Apr 11. J Am Coll Cardiol. 2007. PMID: 17498584 Free article. Clinical Trial.
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
Wang TH, Bhatt DL, Fox KA, Steinhubl SR, Brennan DM, Hacke W, Mak KH, Pearson TA, Boden WE, Steg PG, Flather MD, Montalescot G, Topol EJ; CHARISMA Investigators. Wang TH, et al. Among authors: steg pg. Eur Heart J. 2007 Sep;28(18):2200-7. doi: 10.1093/eurheartj/ehm274. Epub 2007 Aug 2. Eur Heart J. 2007. PMID: 17673448 Clinical Trial.
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk.
Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G, Johnston SC, Steinhubl SR, Mak KH, Easton JD, Hamm C, Hu T, Fox KA, Topol EJ; Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators. Eikelboom JW, et al. Among authors: steg pg. Circulation. 2008 Oct 21;118(17):1705-12. doi: 10.1161/CIRCULATIONAHA.108.768283. Epub 2008 Oct 6. Circulation. 2008. PMID: 18838564 Clinical Trial.
The Essen stroke risk score predicts recurrent cardiovascular events: a validation within the REduction of Atherothrombosis for Continued Health (REACH) registry.
Weimar C, Diener HC, Alberts MJ, Steg PG, Bhatt DL, Wilson PW, Mas JL, Röther J; REduction of Atherothrombosis for Continued Health Registry Investigators. Weimar C, et al. Among authors: steg pg. Stroke. 2009 Feb;40(2):350-4. doi: 10.1161/STROKEAHA.108.521419. Epub 2008 Nov 20. Stroke. 2009. PMID: 19023098
Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry.
Cacoub PP, Abola MT, Baumgartner I, Bhatt DL, Creager MA, Liau CS, Goto S, Röther J, Steg PG, Hirsch AT; REACH Registry Investigators. Cacoub PP, et al. Among authors: steg pg. Atherosclerosis. 2009 Jun;204(2):e86-92. doi: 10.1016/j.atherosclerosis.2008.10.023. Epub 2008 Oct 31. Atherosclerosis. 2009. PMID: 19054514
1,187 results